This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Ironwood Pharmaceuticals To Host Webinar On Accounting Treatment For LINZESS™ (Linaclotide)

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced it will be hosting a webinar to provide an overview of how LINZESS will be reflected in Ironwood’s quarterly income statements following its commercial availability in the U.S. Ironwood will co-commercialize the product in the U.S. through its collaboration with Forest Laboratories, Inc.

The webinar will take place on Tuesday, November 6, 2012 at 12:00 p.m. Eastern Time. Individuals interested in participating in the webinar should visit the Investors section of Ironwood’s website at www.ironwoodpharma.com; please log on at least 15 minutes prior to the start of the event to ensure adequate time for any software downloads that may be required. For listen-only participation, the webinar can also be accessed by dialing (866) 437-1772 (U.S. and Canada) or (973) 638-3229 (international) and use the conference ID number 45259150.

A replay of the webinar will be available on Ironwood’s website or via telephone starting November 6, 2012 at approximately 3:00 p.m. Eastern Time, running through 11:59 p.m. Eastern Time on November 13, 2012. To listen to the replay by phone, dial (855) 859-2056 (U.S. and Canada) or (404) 537-3406 (international) and use conference ID number 45259150.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals (NASDAQ: IRWD) is an entrepreneurial pharmaceutical company dedicated to the art and science of great drugmaking. Ironwood is located in Cambridge, Mass. To learn more, visit www.ironwoodpharma.com.

Copyright Business Wire 2010

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,084.70 -13.75 -0.08%
S&P 500 2,004.04 +0.67 0.03%
NASDAQ 4,595.0030 +14.7320 0.32%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs